Broader approval received in Hong Kong for Nerve Cuff
Filed with ASX · · 3 pages · English
ReNerve Limited (ASX, "ReNerve" or "the Company"), a leading Australian medical device innovator focused on solutions for peripheral nerve injury (PNI), is pleased to announce that its NervAlign® Nerve Cuff has received listing approval in Hong Kong. This facilitates extending previous access to the product to public hospitals as well as the private hospital systems in the Hong Kong region, includ
Story so far
Earlier from Renerve
- ReNerve AGM Presentation
- ReNerve completes $3.2m capital raising
- Trading Halt
- Nerve Cuff approved for use in US DoD and VA hospitals
- ReNerve Clinical Study Expansion
Later from Renerve
- ReNerve receives approval in Malaysia
- Q2 FY26 Activities Report and Appendix 4C
- 1HFY26 Appendix 4D and Half Year Report
- 1HFY26 Results Announcement
- Nerve Guide Matrix Enters Stage 3 of Commercial Development
Follow Renerve into a list and get an email when it puts out news.
Follow Renerve